Sign In
Buy GSK
$50.67
-1.48 (-2.84%)
At Close: Jun 18, 2026
GSK hikes outlook as sales and earning grow faster than expected
04:06am, Wednesday, 29'th Oct 2025
GSK PLC (LSE:GSK, NYSE:GSK) raised its outlook for the full year after beating expectations with third-quarter revenues and earnings per share. Group revenues for the FTSE 100 drugmaker came in at £
GSK raises 2025 sales forecast after strong growth in specialty medicines
03:10am, Wednesday, 29'th Oct 2025
GSK raised its 2025 sales expectations on Wednesday after third-quarter results beat expectations, driven by double-digit growth in its specialty medicines, including HIV and oncology.
Here's Why GSK (GSK) is a Strong Growth Stock
10:46am, Tuesday, 28'th Oct 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
GSK cancer drug wins EU orphan status for small-cell lung cancer
03:51am, Tuesday, 28'th Oct 2025
GSK PLC (LSE:GSK, NYSE:GSK) has secured Orphan Drug Designation in the European Union for GSK5764227, also known as GSK'227, a B7-H3-targeted antibody-drug conjugate being tested in small-cell lung c
GSK Crumbles As Blood Cancer Comeback Falls Unexpectedly Short
09:24am, Friday, 24'th Oct 2025
GSK stock crumbled Friday after the FDA granted its blood cancer treatment, Blenrep, a narrower-than-expected approval.
GSK shares fall as narrow approval of blood cancer drug limits US relaunch
07:24am, Friday, 24'th Oct 2025
GSK's London-listed shares fell nearly 2% on Friday after the U.S. Food and Drug Administration approved only one of two treatment combinations with the British firm's blood cancer drug, limiting the
FTSE 100 Index shares to watch: HSBC, Standard Chartered, Haleon, GSK
01:23am, Friday, 24'th Oct 2025
The FTSE 100 Index rose for four consecutive days and reached its all-time high of £9,578 as traders reacted to key earnings and macro data. It has jumped by over 27% from its lowest level this year.
Blenrep approved by US FDA for use in treatment of relapsed/refractory multiple myeloma
08:11pm, Thursday, 23'rd Oct 2025
PHILADELPHIA--(BUSINESS WIRE)-- #BelantamabMafodotin--Blenrep approved by US FDA for use in treatment of relapsed/refractory multiple myeloma.
US FDA approve GSK's blood cancer treatment
04:05pm, Thursday, 23'rd Oct 2025
The U.S. Food and Drug Administration has approved British drugmaker GSK's blood cancer drug, Blenrep, in combination with other treatments, the company said on Thursday, paving the way for a relaunch
GSK (GSK) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
11:07am, Wednesday, 22'nd Oct 2025
Glaxo (GSK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why GSK (GSK) is a Strong Momentum Stock
10:51am, Tuesday, 21'st Oct 2025
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why GSK (GSK) is a Strong Value Stock
10:41am, Monday, 20'th Oct 2025
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
UK's drug-cost watchdog recommends use of GSK unit's HIV prevention drug
07:02pm, Thursday, 16'th Oct 2025
The UK's drugs cost-effectiveness watchdog has given a positive recommendation for ViiV Healthcare's HIV drug, enabling access to the preventive medicine via the state health system in England and Wal
GSK: Compelling Value, No Red Flags Ahead Of Earnings, Blenrep FDA Decision Soon
02:57pm, Friday, 10'th Oct 2025
GSK plc aka GlaxoSmithKline is rated a Buy at or below $45 due to relative undervaluation and a balanced, diversified portfolio. GSK's recent CEO transition and solid Q2 earnings have improved market
GSK's Hidden Growth Engines Beyond HIV And Oncology
01:22pm, Thursday, 09'th Oct 2025
GSK continues to successfully develop its oncology franchise. So, sales of its "gem" in the treatment of myelofibrosis, called Ojjaara, reached $183 million in the second quarter of 2025, increasing b
